Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
AssigneeJazz Pharmaceuticals Research UK Limited
InventorsDaniel Adam Checketts, Kevin James Craig
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
Claims13
A method of treating seizures associated with a PCDH19 mutation in a patient in need thereof comprising administering a cannabidiol (CBD) drug substance to the patient in need thereof, wherein the CBD drug substance comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC).
Dependencies are inferred from the claim text.